PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Timothy C. Thompson

Serial No.: Unknown

Filed: October 22, 2003

For: SOLUBLE KERATIN PEPTIDE

Group Art Unit: Unknown

Examiner: Unknown

Atty. Dkt. No.: PRO025/4-9CONUS

INFORMATION DISCLOSURE STATEMENT

CERTIFICATE OF EXPRESS MAILING

NUMBER: <u>EV 253711626 US</u>

DATE: October 22, 2003

This paper or fee is being deposited U.S. Postal Service "EXPRESS MAIL POST OFFICE TO ADDRESSEE" service on the date indicated above and is addressed to: Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450,

Alexandria, VA 22313-1450.

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on the attached Form PTO-1449 be considered by the Examiner and made of record. Copies of all references have already been submitted in Applicant's parent application U.S. Serial No. 10/151,055 and those copies are not duplicated in this Information Disclosure Statement.

In accordance with 37 C.F.R. §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be

393805_1.DOC 1

an admission that the information cited is, or is considered to be, material to patentability as

defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first

Official Action reflecting an examination on the merits, and hence is believed to be timely filed

in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the

filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R.

§§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner

is hereby authorized to deduct said fees from Vinson & Elkins L.L.P. Deposit Account

No. 22-0365/PRO025/4-9CON2US.

Respectfully submitted,

Timothy S. Corder Reg. No. 38,414

Agent for Applicant

Vinson & Elkins L.L.P. 2300 First City Tower 1001 Fannin

Houston, Texas 77002-6760

512-542-8446

Date:

October 22, 2003

FORM PTO-1449 (Modified) U.S. DEPARTMENT OF COMMERCE ATTY. DOCKET NO. APPLICATION NO. (REV. 7-80) PATENT AND TRADEMARK OFFICE PRO025/4-9CON2US Not Yet Assigned APPLICANT Timothy C. Thompson LIST OF REFERENCES CITED BY APPLICANT FILING DATE **GROUP** (Use several sheets if necessary) October 22, 2003 Unknown U.S. PATENT DOCUMENTS EXAMINER INITIAL DOCUMENT NUMBER DATE FILING DATE IF APPROPRIATE NAME CLASS SUBCLASS 3 Α 4 7 8 3/2/82 1 Benson, et al. В 4 9 2 5 8 3 5 5/15/90 Heston \mathbf{C} 5 1 1 6 6 1 5 5/26/92 Gokcen, et al. 5 D 2 6 0 2 2 4 11/9/93 Stossel et al. E 5 6 3 3 -1 6 1 5/22/97 SHYJAN F 5 7 8 3 1 2 8 7/21/98 Thompson 5 G 8 4 2 3 4 11/10/98 Gallo FOREIGN PATENT DOCUMENTS TRANSLATION DOCUMENT NUMBER DATE COUNTRY CLASS SUBCLASS YES Н WO 86/ 0 2 6 6/86 WIPO I wo 94/ 0 4 1 9 6 3/3/94 **WIPO** ·J wo 94/ 1 6 7 3 7 8/4/94 WIPO (corres. to AU 62320) K WO 94/ 8 1 2 9 12/94 **WIPO** L WO 95/ 1 9 -3 6 9 7/95 **WIPO** M WO 96/ 3 0 3 8 9 10/96. **WIPO** N wo 97/ 0 9 0 5 5 3/13/97 **WIPO** 0 WO 97/ 1 8 4 5 4 5/22/97 **WIPO** P wo 99/ 2 7 3 5/14/99 WIPO OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.) WELCH, Danny R., et al. "Transforming growth factor β stimulates mammary adenocarcinoma cell invasion and Q metastatic potential", Proc. Natl. Acad. Sci. USA, Vol. 87, pp. 7678-7682. October 1990. THOMPSON, Timothy C., et al. "Multistage Carcinogenesis Induced by ras and myc Oncogenes in a Reconstituted R Organ", Cell, Vol. 56, pp. 917-930. March 24, 1989 **EXAMINER** DATE CONSIDERED *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

		U.S. DEPARTMENT OF COMMERC PATENT AND TRADEMARK OFFIC		ATTY. DOCKET NO.	APPLICATION NO.	
		TATEM AND TRADEMA	KK OFFICE	PRO025/4-9CON2US	Not Yet Assigned	
				APPLICANT		
7	IOT OF DEFEDE	NOTE OFFICE DAY AND LOAD	(m)	Timothy C. Thompson		
1	LIST OF REFERE	NCES CITED BY APPLICAN	Τ	FILING DATE	GROUP	
(Use several sheets if necessary)				October 22, 2003	Unknown	
S	FINGERT et al. Publication, 84-	, "In vivo model for differentiati 2635, Serno Symposia Publicati	on therapy of leuk ons from Rven. Pro	emia and solid tumors." Nati ess, pp. 277-286 (1984)	onal Institutes of Health	
Т	Taber's Cyclope	edic Medical Dictionary, F.A. Da	vid Company, Phi	Philadelphia, PA, edited by Vardara et al. (1993)		
U	LIANG, Peng, e Epithelial Cells'	et al., "Differential Display and C", Cancer Research, 52, pp. 6966	Cloning of Messens -6968. December	ger RNAs from Human Brea 15, 1992.	st Cancer versus Mammary	
V	Carcinomas in I	Elevated Transforming Growth Fa Reconstituted Mouse Prostate: E Vol. 5, No. 4, (1991) pp. 503-51	videnced for a Para	RNA Levels are Associated vacrine Role during Progression	with ras + myc-Induced on". Molecular	
W	Poster Session Abstracts: First SPORE Investigators' Meeting, "The Role of Retinoids in Prostate Cancer Chemoprevention" July 18-20, 1993, page 30.					
Х	SLAWIN, et al. "Dietary Fenretinide, a Synthetic Retinoid, Decreases the Tumor Incidence and the Tumor Mass of ras + myc-induced Carcinomas in the Mouse Prostate Reconstitution Model System", CANCER RESEARCH, Vol. 53, pp. 4461-4465, October 1, 1993					
Y	THOMPSON, et al. "Transgenic Models for the Study of Prostate Cancer", (Supplement) CANCER, Vol. 71, No. 3, Feb. 1, 1993, pp. 1165-1171.					
Z .	DONEHOWER, et al. "Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours", ARTICLES, NATURE, Vol. 356, March 19, 1992, pp. 215-221.					
AA	THOMPSON, et al.," Loss of p53 function leads to metastasis in ras + myc-initiated mouse prostate cancer", Oncogene (1995) Vol. 10, pp. 869-879.					
ВВ	MACOSKA, et al. "Loss of the 17p Chromosomal Region in a Metastatic Carcinoma of the Prostate", <i>The Journal of Urology</i> , Vol. 147, April 1992, pp. 1142-1146.					
CC	TAYLOR, et al. "Evidence for synergistic interactions between ras, myc and a mutant form of p53 in cellular transformation and tumor dissemination", Oncogene, February 10, 1992, pp. 1383-1390.					
DD	HALL, et al. "A	denylate Kinase: An Oncodevel MISTRY, Vol. 31, No. 10, (1985)	opmental Marker i		an Prostatic Cancer",	
EE	THOMPSON, et al., Multistage Carcinogenesis Induced by ras and myc Oncogenes in a Reconstituted Organ, Cell, Vol. 56, pp. 917-930, March 24, 1989					
FF	SLAWIN, et al., "American Urological Association, Inc., Annual Meeting - San Antonio, October 1, 1992, "Dietary Retinoids Decrease the Incidence and Increase Lymphocytic Infiltration of ras + myc Induced Carcinomas in the Mouse Prostate Reconstitution Model System					
GG	THOMPSON, et al "Transforming Growth Factor β1 as a Biomarker for Prostate Cancer", Journal of Cellular Biochemistry, Supplement 16H: pp. 54-61 (1992)					
НН	THOMPSON et Carcinogenesis i	al. "Genetic Predisposition and l n Reconstituted Mouse Prostate"	Mesenchymal-Epit Molecular Carcin	helial Interactions in ras + m logenesis, Vol. 7, pp. 165-17	yc-Induced 9 (1993).	
KAMINER			DATE CONSI	DERED		
XAMINER: Informance and	nitial if reference of not considered. Ir	onsidered, whether or not citation clude a copy of this form with n	n is in conformancext communication	e with MPEP 609; Draw line to applicant.	e through citation if not in	

		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.	APPLICATION NO.	
		TATENT AND TRADEWARK OFFICE	PRO025/4-9CON2US	Not Yet Assigned	
			APPLICANT	<u> </u>	
LICT OF DEFENDACES OF THE TAXABLE PROPERTY.		NOTE CHIEF DAY 1 DAY 2	Timothy C. Thompson	Timothy C. Thompson	
. *	LIST OF REFERENCES CITED BY APPLICANT		FILING DATE	GROUP	
	(Use sev	eral sheets if necessary)	October 22, 2003	Unknown	
II	BOOKSTEIN et al. "p53 Is Mutated in a Subset of Advanced-Stage Prostate Cancer ¹ ", Cancer, Vol. 53, pp July 19, 1993.				
JJ	CARTER, et al Quantification	"Prediction of Metastatic Potential in an Anima of Cell Surface Charge", <i>The Journal of Urology</i>	al Model of Prostate Cancer: Floy, Vol. 142, pp. 1338-1341, Nov	ow Cytometric ember 1989.	
KK	FOX, et al. "p53 And c-myc Expression in Stage A1 Prostatic Adenocarcinoma: Useful Prognostic Determinants?" The Journal of Urology, Vol. 150, pp. 490-494, August 1993.				
LL	EINSTEIN, "Hormonal Therapy for Prostate Cancer - When to Use it", Cancer Control, January/February 1995, pp. 32 36.				
MM	THOMPSON, et al., "Loss of p53 Function Leads to Metastasis in ras + myc- Initiated Mouse Prostate Cancer", Abstraction for Fogarty International Meeting, June 26-28, 1995				
NN	XIONG, et al. "Human D-Type Cyclin, "Cell, Vol. 65: pp. 691-699 (May 17, 1991)				
. 00	MANAM, et al., "Dose related changes in the profile of ras mutations in chemically induced CD-1 mouse liver tumors," Carcinogenesis, Vol. 16(5) pp. 1113-1119 (May 1995)				
PP	BLOK, et al., "Isolation of cDNA's that are differentially expressed between antrogen-dependent and androgen independent prostate carcinoma cells using differential display PCR." <i>Prostate</i> , Vol. 26(4), pp. 213-224 (April 1995)				
QQ	WU, et al. "Identification of a human hepatocellular carcinoma-associated tumor suppressor gene by differential display polymerase chain reaction," <i>Life Sciences</i> , Vol. 57(11), pp. 1077-1085 (Nov. 1995)				
RR	SCHNEIDER, et al. "7,12-Dimethylben[a] anthracene-Induced Mouse Keratinocyte Malignant Transformation Independent of Harvey ras Activation," <i>J. of Investigative Dermatology</i> , Vol. 101(4), pp. 595-599 (Oct. 1993).				
SS	NEUMANN, H.G., "entstehung und Behandlung von Turoren, Immunosupressiva", Allgemeine und Specielle Pharmakologie and Toxikologie, Edition 5. 1987.				
TT	SCHLAG P.M., "Fruherkennung von Krebs mit Hilfe von molekulariologischen Markern", Onkologie, 18, pp. 207, 1995				
UU	TRUONG, et al. "Association of Transforming Growth Factor-β, with Prostate Cancer: An Immunohistochemical Study," Human Pathology, Vol. 24, No. 1, pp. 4-9 (January 1993)				
VV	AIHARA, et al., "Frequency of Apoptotic Bodies Positively Correlates with Gleanson Grade in Prostate Cancer," <i>Human Pathology</i> , Vol. 25, No. 8, pp. 797-801 (August 1994)				
ww	EGAWA, et al., "Alterations in mRNA levels for Growth-Related Genes after Transplantation into Castrated Hosts in Oncogene-Induced Clonal Mouse Prostate Carcinoma," <i>Molecular Carcinogenesis</i> , Vol. 5, pp. 52-61 (1992)				
AMINER	· .	DATE CO	NSIDERED		
XAMINER: I	nitial if reference of	onsidered, whether or not citation is in conform aclude a copy of this form with next communica	ance with MPEP 609; Draw line	through citation if not i	

40314 vas DC (1310/43) DCC)

		U.S. DEPARTMENT OF COMPATENT AND TRADEMARK		ATTY. DOCKET NO. PRO025/4-9CON2US	APPLICATION NO. Not Yet Assigned	
				APPLICANT	Tion Tet Assigned	
·				Timothy C. Thompson		
]	LIST OF REFERI	ENCES CITED BY APPLICANT	•	FILING DATE	GROUP	
(Use several sheets if necessary)				October 22, 2003	Unknown	
XX	GLENNEY, "The Journal of	yrosine Phosphorylation of a 22-kD Biological Chemistry, Vol. 264, No.	a Protein is Cor 34, pp. 20163-	related with Transformation 20166 (1989)	by Rous Sarcoma Virus,'	
YY	CHEN, et al., "Isolation and Characterization of the Promoter Region of Human nm23-H1, a Metastasis Suppressor Gene," Abstract 122:2406 (1994)					
ZZ	SARGIACOMO, et al., "Oligomeric Structure of Caveolin: Implications for Caveoale Membrance Organization," Proc. Natl. Acad. Sci. USA, Vol. 92, pp. 9407-9411 (September 1995)					
AAA	TULCHINSKY, et al., "Transcriptional analysis of the mts1 gene with specific reference to 5' flanking sequences," Proc. Natl. Acad. Sci. USA, Vol. 89, pp. 9146-9150 (October 1992)					
BBB	YANG, et al. " 446, Abstract #	Association of Caveolin Protein with 1742 (April 1997)	Prostate Cance	er Progression", Journal of U	<i>Irology</i> , Vol. 157, No. 4,	
CCC	EASTHAM, et al. "Prostate Cancer Gene Therapy: Herpes Simplex Virus Thymidine Kinase Gene Transduction Followed By Ganciclovir in Mouse and Human Prostate Cancer Models", <i>Human Gene Therapy</i> , Vol. 7, pp. 515-523. March 1, 1996.					
DDD	REN, et al. "Identification and characterization of p53 regulated genes in a mouse prostate cancer cell line". AACR Annual Meeting, March 28-April 1, 1998, New Orleans, LA					
EEE	GOLTSOV, et al. "A novel p53-regulated gene encoding a four transmembrane domain protein in mouse prostate cancer cells", AACR Annual Meeting, April 10-14, 1999, Philadelphia, PA					
FFF	REN, et al. "Reduced Lysyl Oxidase in RNA Levels in Experimental and Human Prostate Cancer", Cancer Research, Vol. 58, pp. 1-6, March 15, 1998					
GGG	NELSON, Joel B. "Alternatives to death: Understanding androgen-independent prostate cancer", <i>Nature Medicine</i> , Vol. 4, No. 9, pp. 1011-1012, September 1998					
ННН	YANG et al. "Elevated Expression of Caveolin Is Associated With Prostate and Breast Cancer", Clinical Cancer Research, Vol. 4, pp. 1873-1880, August 1998					
III	FIELDING, et al. "Caveolin mRNA levels are up-regulated by free cholesterol and down-regulated by oxysterols in fibroblast monolayers", <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 94, pp. 3753-3758, April 1997					
111	NASU, et al. "Suppression of caveloine expression induces androgen sensitivity in metastatic androgen-insensitive mouse prostate cancer cells", <i>Nature Medicine</i> , Vol. 4, No. 9, pp. 1062-1064, September 1998					
KKK	BIST, et al. "Two sterol regulatory element-like sequences mediate up-regulation of caveolin gene transcription in response to low density lipoprotein free cholesterol", <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 94, pp. 10693-10698, September 1997					
LLL	LI, et al. "Src T Caveolin". The	yrosine Kinases, G_{α} Subunits, and H Journal of Biological Chemistry, V	-Ras Share a Cool. 271, No. 46,	ommon Membrane-anchored pp. 29182-29190, 1996.	Scaffolding Protein,	
XAMINER			DATE CONS	IDERED		
EXAMINER: onformance and	Initial if reference	considered, whether or not citation is neclude a copy of this form with next	s in conformance	e with MPEP 609; Draw line	e through citation if not in	

FORM PTO-1		MERCE	ATTY. DOCKET NO.	APPLICATION NO.	
(REV. 7-80) PATENT AND TRADEMAR		CK OFFICE	PRO025/4-9CON2US	Not Yet Assigned	
			APPLICANT		
	I ICT OF DEPENDANCE COMME		Timothy C. Thompson		
	LIST OF REFERENCES CITED BY APPLICANT		FILING DATE	GROUP	
	(Use several sheets if necessary)		October 22, 2003	Unknown	
MMM	EASTHAM, et al. "In Vivo Gene Therapy with p53 o 5151-5155, November 15, 1995	r p12 Adenov	irus for Prostate Cancer", Ca	ancer Research, Vol. 55, p.	
NNN	EASTHAM, et al. "Transforming Growth Factor- β_1 : and Metastatic Prostate Cancer", Laboratory Investig	Comparative I	mmunohistochemical Local , No. 5, pp. 628-635 (1995)	ization in Human Primary	
000	AIHARA, et al. "The Frequency of Apoptosis Correla Prostate". Cancer, Vol. 75, No. 2, Pp. 522-529 (Jan. 1	ates with the P		3 Adenocarcinoma of the	
PPP	YANG, et al., "Perineural Invasion of Prostate Carcinoma Cells is Associated with Reduced Apoptotic Index", Cancer, Vol. 78, No. 6, pp. 1267-1271 (Sept. 15, 1996)				
QQQ	CHAMNESS, et al., "The effect of androgen on nitric oxide synthase in the male reproductive tract of the rat", Fertility and Sterility, Vol. 63, No. 5, pp. 1101-1107 (May 1995)				
RRR	STAPLETON, et al., "Primary Human Prostate Cancer Cells Harboring p53 Mutation are Clonally Expanded in Metastates", Clinical Cancer Research, Vol. 3, pp. 1389-1397 (Aug. 1997)				
SSS	KOLESKE, et al., "Reduction of caveolin and caveolae in oncogenically transformed cells", <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 92, pp. 1381-1385 (Feb. 1995)				
TTT	KAGAN, Herbert M., "Regulation of Matrix Accumulation", Academic Press, Inc., pp. 321-398 (1986)				
UUU	KAGAN, et al., "Properties and Function of Lysyl Oxidase", AM. J. Respir. Cell Mol. Biol., Vol. 5, pp. 206-210 (1991)				
VVV	AIHARA, et al., "Frequency of Apoptotic Bodies Positively Correlates with Gleason Grade in Prostate Cancer", Human Pathology, Vol. 25, No. 8, pp. 797-801 (Aug. 1994)				
www	FERES-FILHO, et al., "Pre- and Post-translational Regulation of Lysyl Oxidase by Transforming Growth Factor-β1 in Osteoblastic MC3T3-E1 Cells", <i>The Journal of Biological Chemistry</i> , Vol. 270, No. 51, pp. 30797-30803 (Dec. 22, 1995)				
XXX	SHANLEY, et al., "Transforming growth factor-β ₁ increases lysyl oxidase enzyme activity and mRNA in rat aortic smooth muscle cells", <i>Journal of Vascular Surgery</i> , Vol. 25, No. 3, pp. 446-452 (March 1997)				
YYY	BOAK, et al., "Regulation of Lysyl Oxidase Expression in Lung Fibroblasts by Transforming Growth Factor-β ₁ and Prostaglandin E ₂ ", American Journal of Respiratory Cell and Molecular Biology, Vol. 11, pp. 751-755 (1994)				
ZZZ	KAVIRIKKO, et al., "Posttranslational Modifications of Collagen and Their Alterations in Heritable Diseases", pp. 263-292				
AAAA	DANKS, David M., "Disorders of Copper Transport: Menkes Disease and the Occipital Horn Syndrome", Connective Tissue and Its Heritable Disorders, pp. 487-505 (1993)				
BBBB	KIVIRIKKO, Kari L., "Collagens and their Abnormal pp. 113-126 (1993)	ities in a Wide	e Spectrum of Diseases", And	nals of Medicine 25;	
EXAMINER		DATE CONSIDERED			
*EXAMINER: 1 conformance and	Initial if reference considered, whether or not citation is it in not considered. Include a copy of this form with next considered.	n conformance	e with MPEP 609; Draw line to applicant.	e through citation if not in	

EV. 7-80)	49 (Modified)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	MERCE OFFICE	ATTY. DOCKET NO.	APPLICATION NO.	
· · · · · · · · · · · · · · · · · · ·		THE TRUE TRUE DENIMINA	K OFFICE	PRO025/4-9CON2US	Not Yet Assigned	
				APPLICANT		
LIST OF REFERENCES CITED BY APPLIC		CNICEO CITED DA ADDITICANTO		Timothy C. Thompson		
L.			ſΤ	FILING DATE	GROUP	
(Use several sheets if necessary)				October 22, 2003	Unknown	
cccc	CONTENTE, 6 Science, Vol. 2	et al., "Expression of Gene <i>rrg</i> Is Asso 49, pp. 769-798	ciated with R	eversion of NIH 3T3 Transfo	ormed by LTR-c-H-ras",	
DDDD	HAJNAL, et al pp. 4670-4675	., " Up-Regulation of Lysyl Oxidase in	n Spontaneous	s Revertants of H-ras-transfo	ormed Rat Fibroblasts",	
EEEE	THOMPSON, Vol. 4, No. 4, p	et al., "Caveolin-1, a metastasis-related p. 233-237 (1999)	d gene that pr	omotes cell survival in prosta	ate cancer", Apoptosis,	
FFFF	THOMPSON, malignancies",	et al., "Caveolin-1: a complex and pro Emerging Therapeutic Targets 3(2) pp	vocative thera o. 337-346 (19	speutic target in prostate cand	cer and potentially other	
GGGG	TAN, et al., "Identification of the Lysyl Oxidase Gene as a Target of the Antioncogenic Transcription Factor, IRF-1, and Its Possible Role in Tumor Suppression", pp. 2417-2421					
. HHHH	KUIVANIEMI, et al., " Deficient production of olysyl oxidase in cultures of malignantly transformed human cells", FEB. Letters, Vol. 195, No. 1, 2, pp. 261-264 (January 1986)					
IIII	VATER, et al., "Native Cross-Links in Collagen Fibrils Induce Resistance to Human Synovial Collagenase", Biochem J., Vol. 181, pp. 639-645 (1979)					
1333	HÄMÄLÄINEN, et al., "Quantitative Polymerase Chain Reaction of Lysyl Oxidase mRNA in Malignantly Transformed Human Cell Lines Demonstrates That Their Low Lysyl Oxidase Activity Is Due to Low Quantities of Its mRNA and Low Levels of Transcription of the Respective Gene", <i>The Journal of Biological Chemistry</i> , Vol. 270, No. 37, pp. 21590-2159 (Sept. 15, 1995)					
KKKK	PEYROL, et al., "Lysyl Oxidase Gene Expression in the Stromal Reaction to in Situ and Invasive Ductal Breast Carcinoma", American Journal of Pathology, Vol. 150, No. 2, pp. 497-507 (Feb. 1997)					
LLLL	THOMPSON, et al., "Exogenous Leukocyte and Endogenous Elastases Can Mediate Mitogenic Activity in Pulmonary Artery Smooth Muscle Cells by Release of Extracellular Matrix-Bound Basic Fibroblast Growth Factor", Journal of Cellular Physiology, Vol. 166, pp. 495-505 (1996)					
MMMM						
NNNN	SHIMURA, et al. Abstract; American Urological Association 94th Annual Meeting, Dallas, TX, "Reduction in Lysyl Oxidase Expression is an Preditor of Recurrence Following Radical Prostatectomy", May 1-6, 1999.					
0000	THOMPSON, "Metastasis-related Genes in Prostate Cancer: The Role of Caveolin-1", Cancer and Metastasis Reviews, Vol. 17, pp. 439-442, 1999.					
PPPP	GUARINI, et al., "Transfer of the Interleukin-2 Gene into Human Cancer Cells Induces Specific Antitumor Recognition and Restores the Expression of CD3/T-Cell Receptor Associated Signal Transduction Molecules", <i>Blood</i> , Vol. 89, No. 1, pp. 212-218 (January 1, 1997)					
QQQQ	JOURDAN-LE Fibroblast", Jou	SAUX, et al., "Functional Analysis of mal of Cellular Biochemistry 64: 328-	the Lysyl Ox 341, Feb. 199	idase Promoter in Myofibrol	plast-Like Clones of 3T6	
KAMINER			DATE CONSIDERED is in conformance with MPEP 609; Draw line through citation if not in			

FORM PTO-14 REV. 7-80)	149 (Modified)	9 (Modified) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.	APPLICATION NO.	
ratent and the		TATENT AND TRADEMARK OFFICE	PRO025/4-9CON2US	Not Yet Assigned		
				APPLICANT		
LICT OF REFERENCES OVERS THE		CNICEC CUTED DV ADDI ICAA	r ·	Timothy C. Thompson		
•	LIST OF REFERENCES CITED BY APPLICANT			FILING DATE	GROUP	
(Use several sheets if necessary)				October 22, 2003	Unknown	
RRRR	Proceedings of	the American Association for Cancer Re	esearch, Vo	ol. 36, p. 266 #1589. March 1995.		
SSSS	LIANG, Peng,	et al., "Differential Display of Eukaryoti 57, pp. 967-971. August 14, 1992.	ic Messenge	TRNA by Means of the Poly	merase Chain Reaction	
TTTT	WOOD, David P., Jr., et al., "Sensitivity of Immunohistochemistry and Polymerase Chain Reaction in Detecting Prosta Cancer Cells in Bone Marrow", <i>The Journal of Histochemistry and Cytochemistry</i> , Vol. 42, No. 4, pp. 505-511. 1994.					
บบบบ	GUDAS, "Retinoids, Retinoid-responsive Genes, Cell Differentiation, and Cancer", Cell Growth & Differentiation, Vol. 3, pp. 655-662, September 1992.					
VVVV	MOKULIS, et al., "Screening for Prostate Cancer: Pros, Cons, and Reality", Cancer Control, pp. 15-21, January/February 1995.					
www	PARTON, Robert G., "Ultrastructural Localization of Gangiosides; GM 1 is concentrated in Caveolae", The Journal of Histochemistry and Cytochemistry, Vol. 42, No. 2, pp. 155-166					
XXXX	WU, M., et al., "Clustering of GPI-Anchored Folate Receptor Independent of Both Cross-Linking and Associatoin wit Caveolin", <i>The Journal of Membrane Biology</i> , 159, pp. 137-147					
YYYY	GARVER, William S., et al., "Increased Expression of Caveolin-1 in Heterozygous Niemann - Pick Type II Human Fibroblasts", <i>Biochemical and Biophysical Research Communications</i> , 236, pp. 189-193					
ZZZZ	PARTON, Robert G., "Caveolin-3 Associates with Developing T-tubules during Muscle Differentiation", <i>The Journal of Cell Biology</i> , Vol. 136, No. 1, January 13, 1997, pp. 137-154					
AAAAA						
BBBBB	MOORE, Robert H., et al., "Ligand - stimulated B2-adrenergic Receptor Internalization via the Constitutive Endocytic Pathway into rab5-containing Endosomes", <i>Journal of Cell Science</i> , 108, pp. 2983-2991					
cccc	SCHERER, Philipp E., et al., "Caveolin Isoforms Differ in Their N-terminal Protein Sequence and Subcellular Distribution", The Journal of Biological Chemistry, Vol. 270, No. 27, pp. 16395-16401					
DDDDD	BROWN, Dennis, et al., "Antigen Retrievl in Cryostat Tissue Sections and Cultured Cells By Treatment with Sodium Dodecyl Sulfate (SDS)", Histochem Cell Biol, (1996), 105, pp. 261-267					
EEEEE	SONG, Kenneth S., et al., "Expression of Caveolin-3 in Skeletal, Cardiac, and Smooth Muscle Cells", <i>The Journal of Biological Chemistry</i> , Vol. 271, No. 25, pp. 15160-15165					
FFFFF						
AMINER			TE CONSI			
XAMINER: In	nitial if reference of	considered, whether or not citation is in conclude a copy of this form with next com	onformance	with MPEP 609; Draw line	through citation if not in	

40314 00 DO (10111-1----